N
Nicola Relitti
Researcher at University of Siena
Publications - 25
Citations - 404
Nicola Relitti is an academic researcher from University of Siena. The author has contributed to research in topics: Acetylation & Cancer. The author has an hindex of 9, co-authored 22 publications receiving 209 citations. Previous affiliations of Nicola Relitti include Purdue University & University of Naples Federico II.
Papers
More filters
Journal ArticleDOI
Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists.
Stefano Federico,Luca Pozzetti,Alessandro Papa,Gabriele Carullo,Sandra Gemma,Stefania Butini,Giuseppe Campiani,Nicola Relitti +7 more
TL;DR: This perspective will highlight the recent discoveries in this field emphasizing the role of TLR isoforms in different diseases, the therapeutic effect of their natural and synthetic modulators and will discuss insights for the future exploitation of TLRs modulators in human health.
Journal ArticleDOI
Structure-based discovery of the first non-covalent inhibitors of Leishmania major tryparedoxin peroxidase by high throughput docking
Margherita Brindisi,Simone Brogi,Nicola Relitti,Nicola Relitti,Alessandra Vallone,Stefania Butini,Sandra Gemma,Ettore Novellino,Ettore Novellino,Gianni Colotti,Gabriella Angiulli,Francesco Di Chiaro,Annarita Fiorillo,Andrea Ilari,Giuseppe Campiani +14 more
TL;DR: The high-resolution structure of Tryparedoxin peroxidase I from Leishmania major (LmTXNPx) in the reduced state and in fully folded conformation is solved and could pave the way to the discovery of a new class of drugs against leishmaniasis.
Journal ArticleDOI
Autophagy modulators for the treatment of oral and esophageal squamous cell carcinomas
Tuhina Khan,Nicola Relitti,Margherita Brindisi,Stefania Magnano,Daniela M. Zisterer,Sandra Gemma,Stefania Butini,Giuseppe Campiani +7 more
TL;DR: An overview of the available biomarkers and innovative targeted therapeutic strategies, including the application of autophagy modulators in OSCC and ESCC is given, and a viewpoint on the state of the art and on future therapeutic perspectives combining the early detection of relevant biomarkers with drug discovery is provided.
Journal ArticleDOI
Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials.
Nicola Relitti,Akella P. Saraswati,Stefano Federico,Tuhina Khan,Margherita Brindisi,Daniela M. Zisterer,Simone Brogi,Sandra Gemma,Stefania Butini,Giuseppe Campiani +9 more
TL;DR: The current status of telomerase-based cancer therapeutics and the outcome of these investigations are highlighted.
Journal ArticleDOI
Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors
A Prasanth Saraswati,Nicola Relitti,Margherita Brindisi,Sandra Gemma,Daniela M. Zisterer,Stefania Butini,Giuseppe Campiani +6 more
TL;DR: Recent advances in the development of telomerase inhibitors as anticancer agents are outlined and differential expression has been exploited to develop highly specific and potent cancer therapeutics.